Skip to main content

Anti-NMDA Receptor Encephalitis clinical trials at UC Irvine

1 research study open to eligible people

Showing trials for
  • ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis

    open to eligible people ages 18 years and up

    Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.

    Orange, California and other locations

Our lead scientists for Anti-NMDA Receptor Encephalitis research studies include .

Last updated: